The Filing Desk

Alumis vs NewAmsterdam Pharma

Alumis ALMS · NewAmsterdam Pharma NAMS · Pharmaceuticals

Alumis reported revenue of $24 million in fiscal 2025, about the same as NewAmsterdam Pharma's $22 million in fiscal 2025. Alumis had an operating margin of -1886.9%, against -1002.9% at NewAmsterdam Pharma. Free cash flow was −$370 million at Alumis and −$148 million at NewAmsterdam Pharma.

Side by side

AlumisNewAmsterdam Pharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$24M$22M
Revenue growth—−50.6%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin−1,886.9%−1,002.9%
Net margin−1,011.8%−905.7%
Free cash flow−$370M−$148M
Free cash flow margin−1,539.2%−657.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count200.0%25.5%
Last close$4.33$19.51
P/E at the last close——
Insider trades, last 12 monthsbought $34.3 million, sold $1.5 millionbought $226,500, sold $62.0 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AlumisNewAmsterdam Pharma
Operating margin
Percent of revenue
AlumisNewAmsterdam Pharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlumisNewAmsterdam Pharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alumis and NewAmsterdam Pharma pages.